Research programme: bispecific cancer antibody - Antibody Therapeutics
Latest Information Update: 30 Aug 2021
At a glance
- Originator Antibody Therapeutics
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Adenocarcinoma; Breast cancer; Lung cancer; Solid tumours
Most Recent Events
- 30 Aug 2021 Bispecific cancer antibody - Antibody Therapeutics is available for licensing as of 30 Aug 2021. https://www.antibodytherapeutics.com/company/
- 30 Aug 2021 Early research in Adenocarcinoma in USA (Parenteral) prior to August 2021 (Antibody Therapeutics pipeline, August 2021)
- 30 Aug 2021 Early research in Breast cancer in USA (Parenteral) prior to August 2021 (Antibody Therapeutics pipeline, August 2021)